All Stories
Follow
Subscribe to AGENNIX AG i.L.

AGENNIX AG i.L.

EANS-News: Agennix AG Schedules Conference Call on May 9 to Discuss First Quarter 2012 Financial Results

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
3-month report


Planegg/Munich (Germany), Princeton, NJ and Houston, TX, May 2, 2012 (euro
adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the
Company will host a conference call to discuss first quarter 2012 financial
results and provide a business update on May 9, 2012.

The conference call, which will be conducted in English, will be held on
Wednesday, May 9, 2012 at 3 PM CET/9 AM ET. The Company's financial results will
be published in advance of the conference call. 

A live webcast will be available on the Agennix Web site at www.agennix.com.
A replay will be available via the Web site following the live event. 

Dial-in numbers for the call are as follows: 


Participants from Europe:       0049 (0)69 710 445 598
                                0044 (0)20 3003 2666
Participants from the U.S.:     1 212 999 6659


Please dial in 10 minutes before the beginning of the call.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially lengthen
and improve the lives of critically ill patients in areas of major unmet medical
need. The Company's most advanced investigational agent is talactoferrin, a
first-in class oral Dendritic Cell Mediated Immunotherapy (DCMI). Talactoferrin
is currently in Phase III clinical trials in non-small cell lung cancer. Other
clinical development programs include RGB-286638, a multi-targeted kinase
inhibitor in Phase I testing for cancer, and a topical gel form of talactoferrin
for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany.
The Company has three sites of operation: Planegg/Munich, Germany; Princeton,
New Jersey and Houston, Texas. For additional information, please visit the
Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. The achievement of
positive results in early stage clinical studies does not ensure that later
stage or large scale clinical studies will be successful.  Even if the results
from our later stage trials with talactoferrin, including the ongoing FORTIS-M
trial in non-small cell lung cancer, are considered positive, there can be no
guarantee that they will be sufficient to gain marketing approval in the United
States or any other country, and regulatory authorities may require additional
information, data and/or further pre-clinical or clinical studies to support
approval.  In such event, there can be no guarantee that the Company will have
or be able to obtain the financial resources to conduct any such additional
studies or that such studies will yield results sufficient for approval. 
Forward-looking statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking statements,
even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.


Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications 
Phone: +49 (0)89 8565 2693
 
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884 
 
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
 
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Senior Vice President
Phone: +44 207 936 9325 
 
lwilliams@troutgroup.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
mail:         ir@agennix.com
WWW:         http://www.agennix.com
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             regulated dealing/prime standard: Frankfurt 
language:   English

Original content of: AGENNIX AG i.L., transmitted by news aktuell

More stories: AGENNIX AG i.L.
More stories: AGENNIX AG i.L.